Gastric cancer treatment market to grow at the rate of 14.6% annually to $4.4 billion by 2024

22 December 2015

The treatment market for gastric and gastroesophageal junction adenocarcinoma (gastric cancer) will witness a rapid 14.6% annual growth, to reach $4.39 billion by 2024 from $1.13 billion in 2014, according to a report from the research firm GlobalData.

The market will be driven by the increasing incidences of gastric cancer and the launch of premium-priced treatment for advanced or metastatic disease, according to the report.

Fenix Leung, senior analyst at GlobalData, says that while growth will be very positive across the leading eight markets (8MM), it will be strongest across the five major European markets (5EU), as sales will increase from $301 million in 2014 to $1.49 billion by 2024, at a robust compound annual growth rate (CAGR) of 17.3%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK